066ATZ
066ATZ is a PIP4K2A/2B inhibitor with human PIP4K2A Ki 100 nM and PIP4K2B Ki 800 nM. 066ATZ binds to ATP-binding sites of PIP4K2A and PIP4K2B to block lipid kinase activity. 066ATZ can be used for the research of non-small cell lung cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C22H23N11OS
- 分子量:489.56
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
体外実験
066ATZ (0.03-20 μM;) potently and selectively inhibits recombinant PIP4K2A (Ki = 170 nM) and PIP4K2B (Ki = 870 nM) in vitro[1].
066ATZ (0.5 μM) demonstrates high selectivity against most human protein kinases, with only CK2a and CK2a2 showing significant inhibition[1].
066ATZ (20 μM; 3 days) does not affect the in vitro growth rate of H1975* NSCLC cells[1].
066ATZ (20 μM) reduces the growth-promoting activity of M2a-polarized THP-1 macrophages towards H1975 NSCLC cells in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:H1975 NSCLC cells
-
Concentration:20 μM
-
Incubation Time:3 days
-
Result:Had no effect on the growth rate of cultured H1975 cells, with cell number fold-change matching that of DMSO-treated control cells.
体内実験
066ATZ (10-100 mg/kg; i.p.; single dose; 4 consecutive daily doses) is well tolerated at doses up to 100 mg/kg in female nude mice, and causes a transient blood glucose drop at doses of 30 mg/kg and higher[1].
066ATZ (10 mg/kg; i.p.; single dose) has a short in vivo half-life of ~0.5 h in male C57BL/6 mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rag2/IL2RG double knockout (R2G2) (female, 7 weeks old, 1 × 107 H1975 cells was injected subcutaneously to establish a xenograft model)[1]
-
Dosage:100 mg/kg
-
Administration:i.p.; 5 times per week for 36 days
-
Result:Reduced average tumor volume significantly compared to vehicle control on day 24 of treatment (p < 0.01).
Showed a small increase in CD31 staining in tumor tissues, indicating enhanced angiogenesis.
-
Animal Model:nude (female)[1]
-
Dosage:10 mg/kg; 30 mg/kg; 100 mg/kg
-
Administration:i.p.; single dose; 4 consecutive daily doses (100 mg/kg only)
-
Result:Caused a transient 14% blood sugar drop 30 min after injection in the 30 mg/kg and 100 mg/kg groups, but not in the 10 mg/kg group.
Showed no difference in steady-state blood glucose after 4 consecutive daily doses of 100 mg/kg.
Did not affect body weight at a dose of 100 mg/kg.
-
Animal Model:C57BL/6 (male)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; single dose
-
Result:Reached a maximum plasma concentration (Cmax) of 2,484 ng/mL (~5.1 μM) after a single dose.
Had a half-life (t1/2) of ~0.5 h.
化学情報
-
分子量 489.56
-
分子式 C22H23N11OS
-
SMILES
CN1C([C@H](N(C2=NC(NC3=CN=C(S3)C4=NNN=N4)=NC=C21)C5CCCC5)CC6=NC=CC=C6)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)